{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:14Z","timestamp":1790969714015,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bone.2023.116764","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T20:02:05Z","timestamp":1681502525000},"page":"116764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study"],"prefix":"10.1016","volume":"172","author":[{"given":"Giovanni","family":"Liebich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2376","authenticated-orcid":false,"given":"Olivier","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Aubry-Rozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-6008","authenticated-orcid":false,"given":"Elena","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2023.116764_bb0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2023.116764_bb0010","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bone.2023.116764_bb0015","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116764_bb0020","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2023.116764_bb0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2023.116764_bb0030","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116764_bb0035","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"The Swiss Denosumab Study, fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116764_bb0040","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","author":"Cosman","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116764_bb0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116764_bb0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116764_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115830","article-title":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study","volume":"144","author":"Everts-Graber","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116764_bb0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bone.2023.116764_bb0065","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2023.116764_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14550","article-title":"Multiple vertebral fractures after suspension of denosumab. A series of 56 cases","volume":"75","author":"Sosa-Henriquez","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.bone.2023.116764_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116764_bb0080","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116764_bb0085","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116764_bb0090","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116764_bb0095","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20352","article-title":"2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss association against osteoporosis (SVGO)","volume":"150","author":"Ferrari","year":"2020","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.bone.2023.116764_bb0100","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116764_bb0105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr. Osteoporos Rep."},{"key":"10.1016\/j.bone.2023.116764_bb0110","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116764_bb0115","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116764_bb0120","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.bone.2023.116764_bb0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2023.116764_bb0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semarthrit.2019.02.007","article-title":"Spontaneous vertebral fractures after denosumab discontinuation: a case collection and review of the literature","volume":"49","author":"Florez","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bone.2023.116764_bb0135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J Clin Densitom."},{"key":"10.1016\/j.bone.2023.116764_bb0140","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","article-title":"Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment","volume":"38","author":"Kondo","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2023.116764_bb0150","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4158\/EP.16.6.1016","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations","volume":"16","author":"Watts","year":"2010","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2023.116764_bb0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/cen.14042","article-title":"Trabecular bone score and bone remodelling markers identify perimenopausal women at high risk of bone loss","volume":"91","author":"Gutierrez-Buey","year":"2019","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.bone.2023.116764_bb0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2023.116764_bb0165","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116764_bb0170","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2023.116764_bb0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","article-title":"Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcif. Tissue Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:06:30Z","timestamp":1757613990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328223000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":34,"alternative-id":["S8756328223000972"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2023.116764","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2023.116764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116764"}}